Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center, describes the advancements in the discussion around avelumab maintenance at this year’s American Society of Clinical Oncology Genitourinary Cancers Symposium, including relevant data from the JAVELIN Bladder 100 and US PATRIOT-II studies, as well as the ongoing MAIN-CAV study.
Avelumab Maintenance for Advanced UC: Updates From JAVELIN Bladder 100, US PATRIOT-II, and More
By Petros Grivas, MD, PhD - Last Updated: May 20, 2024Related Posts
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.